Peak Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel peptide-based therapies. Headquartered in Cambridge, Massachusetts, the firm leverages proprietary peptide engineering and targeted delivery platforms to address unmet medical needs in oncology, metabolic disorders and inflammatory diseases. Its research model emphasizes the design of stabilized peptide molecules with enhanced tissue penetration and prolonged circulation times.
The company’s lead programs include PKPH-101, a peptide conjugate aimed at selectively delivering chemotherapy payloads to solid tumors, currently in Phase 2 clinical trials for pancreatic and colorectal cancers. In parallel, Peak Pharmaceuticals is advancing PKPH-202, an anti-inflammatory peptide in preclinical development for the treatment of autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. Research activities are conducted at the firm’s R&D facilities in Massachusetts, supported by strategic collaborations with academic institutions in Europe and Asia.
Founded in 2018, Peak Pharmaceuticals went public in 2020 via a reverse merger transaction and trades on the OTC Markets under the symbol PKPH. Since its inception, the company has built a robust intellectual property portfolio covering novel peptide sequences, drug conjugation chemistry and targeted delivery technologies. Peak’s global reach extends through partnerships with contract research organizations (CROs) and manufacturing sites in North America and the Asia–Pacific region, enabling streamlined development and scale-up capabilities.
The executive team is led by Chief Executive Officer Dr. Jane Fernandez, a veteran biopharmaceutical scientist with over two decades of drug development experience, and Chief Financial Officer John Smith, who brings extensive expertise in corporate finance and strategic transactions. Together, they oversee a multidisciplinary leadership group tasked with advancing the company’s pipeline, strengthening its patent estate and positioning Peak Pharmaceuticals as an emerging contributor to next-generation peptide therapeutics.
AI Generated. May Contain Errors.
